Drugs News and Research

RSS

Advanced Life Sciences Holdings reports decrease in net loss for full-year 2009

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2009.

11 Mar 2010

NeoMed invests in CytoCore

CytoCore Inc., the developer of cost-effective products used in the practice of cytology for the detection and diagnosis of cancer and cancer related diseases, announced today that NeoMed has made an investment in CytoCore Inc.

11 Mar 2010

USPTO issues patent related to Seattle Genetics' ADC technology

Seattle Genetics, Inc. announced today that the U.S. Patent and Trademark Office has issued a patent related to its antibody-drug conjugate (ADC) technology. U.S. Patent No. 7,659,241 covers cleavable linkers and potent auristatin drug payloads used in certain of Seattle Genetics’ ADC programs, most notably brentuximab vedotin (SGN-35), as well as many ADC programs in development by its collaborators.

11 Mar 2010

Evaluating true toxicity of drugs: Changes in collecting and reporting adverse symptom information needed

A Perspective piece in the New England Journal of Medicine calls for change in the way researchers and pharmaceutical companies collect and report adverse symptom information in clinical trials submitted to the Food and Drug Administration (FDA), and how the FDA represents this information on drug labels.

11 Mar 2010

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company’s 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.

11 Mar 2010

Fewer injections to treat neutropenia in childhood cancer patients

For patients like 10-year-old Sabrina Jo Spence, new research led by St. Jude Children's Research Hospital investigators meant fewer injections to combat the drop in white blood cells following her recent chemotherapy.

11 Mar 2010

Refining treatments to target only key heart-related mechanisms may improve effectiveness

Current drugs used to treat heart failure and arrhythmias (irregular heartbeat) have limited effectiveness and have side effects. New basic science findings from a University of Iowa study suggest a way that treatments could potentially be refined so that they work better and target only key heart-related mechanisms.

11 Mar 2010

Study uncovers mechanism facilitating motivation for alcohol after extended abstinence

New research provides exciting insight into the molecular mechanisms associated with addiction and relapse. The study, published by Cell Press in the March 11 issue of the journal Neuron, uncovers a crucial mechanism that facilitates motivation for alcohol after extended abstinence and opens new avenues for potential therapeutic intervention.

11 Mar 2010

Non-smoked medical cannabis products needed, says National Drug Control Policy Deputy Director

Cannabis Science, Inc., a pioneering US pharmaceutical cannabis company, notes that comments by President Obama's Deputy Director of the White House Office of National Drug Control Policy, Tom McClellan, in yesterday's USA TODAY pinpoints the need for non-smoked medical cannabis products similar to those currently being developed for FDA clinical trials by Cannabis Science.

11 Mar 2010

New changes made to the Dose Conversion Guidelines on Fentanyl Transdermal Systems

The manufacturers of Fentanyl Transdermal Systems, in collaboration with Health Canada, would like to inform Canadians of important new changes made to the Dose Conversion Guidelines in the Product Monograph. These guidelines are used to help determine what dosage of Fentanyl Transdermal Systems is appropriate for each individual patient.

11 Mar 2010

AiDKlinik information system reduces adverse drug interaction numbers

To get life-threatening diseases under control, patients in the intensive care unit usually are administered many medications at the same time. Even for experts, it is difficult to keep track of the variety of possible side effects and interactions.

11 Mar 2010

Following existing cholesterol-lowering target guidelines can prevent more heart disease-related incidents

Only half of all patients at high risk of heart disease are given correct targets for lowering their cholesterol levels according to a study of 25,250 patients in Germany published online today (Thursday 11 March) in the European Heart Journal.

11 Mar 2010

BioInvent International, HGS announce collaboration to develop therapeutic monoclonal antibodies

BioInvent International AB and Human Genome Sciences, Inc. today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies which specifically target antigens discovered by HGS.

11 Mar 2010

Controlling cholesterol using biologically active molecules isolated from algal infusion

Researchers at Wayne State University's Department of Nutrition and Food Science believe they've uncovered a unique method to control and regulate cholesterol using biologically active molecules isolated from ProAlgaZyme™ -- a proprietary algal infusion produced by Health Enhancement Products, Inc., of Scottsdale, Arizona.

11 Mar 2010

Lotus Pharmaceuticals announces groundbreaking ceremony to construct new building complex in Beijing

Lotus Pharmaceuticals, Inc., a growing developer and producer of prescription drugs and licensed national seller of pharmaceutical products in the People's Republic of China, reported the groundbreaking ceremony on March 9 to construct a new building complex on the grounds of its production facility in Beijing.

11 Mar 2010

HGS, BioInvent International AB to discover, develop and commercialize therapeutic monoclonal antibodies

Human Genome Sciences, Inc. and BioInvent International AB today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies that specifically target antigens discovered by HGS.

11 Mar 2010

WHO's updated malaria guidelines include rapid diagnosis, new ACT

The WHO on Tuesday released new guidelines for the treatment of malaria, which recommend "parasitological testing before treatment begins" and add "a new artemisinin based combination treatment [ACT] to the list of prescribed drugs," BMJ News reports.

11 Mar 2010

Injured nerves may cause severe pain in patients with sickle cell disease

Researchers at the University of Illinois at Chicago have discovered the pain caused by sickle cell disease may not occur solely from damaged tissues, but also from injured nerves.

11 Mar 2010

Comparative research lags far behind approval-driven evaluations

A new study has found that few drug evaluations compare treatments in ways that help doctors make better decisions, Reuters reports.

11 Mar 2010

British government, HIV/AIDS advocates warn decreased aid budgets could lead to reversals in HIV/AIDS treatment progress

Recent gains in the global fight against HIV/AIDS could be reversed as the "global economic downturn pinches poor countries' budgets and donors show signs of backing away from their promise to provide universal access to AIDS treatment," the British government together with Medecins Sans Frontieres warned Tuesday, Reuters AlertNet reports.

11 Mar 2010

Drugs News and Research

Advanced Life Sciences Holdings reports decrease in net loss for full-year 2009

NeoMed invests in CytoCore

USPTO issues patent related to Seattle Genetics' ADC technology

Evaluating true toxicity of drugs: Changes in collecting and reporting adverse symptom information needed

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

Fewer injections to treat neutropenia in childhood cancer patients

Refining treatments to target only key heart-related mechanisms may improve effectiveness

Study uncovers mechanism facilitating motivation for alcohol after extended abstinence

Non-smoked medical cannabis products needed, says National Drug Control Policy Deputy Director

New changes made to the Dose Conversion Guidelines on Fentanyl Transdermal Systems

AiDKlinik information system reduces adverse drug interaction numbers

Following existing cholesterol-lowering target guidelines can prevent more heart disease-related incidents

BioInvent International, HGS announce collaboration to develop therapeutic monoclonal antibodies

Controlling cholesterol using biologically active molecules isolated from algal infusion

Lotus Pharmaceuticals announces groundbreaking ceremony to construct new building complex in Beijing

HGS, BioInvent International AB to discover, develop and commercialize therapeutic monoclonal antibodies

WHO's updated malaria guidelines include rapid diagnosis, new ACT

Injured nerves may cause severe pain in patients with sickle cell disease

Comparative research lags far behind approval-driven evaluations

British government, HIV/AIDS advocates warn decreased aid budgets could lead to reversals in HIV/AIDS treatment progress

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News